KLP Kapitalforvaltning AS Sells 740 Shares of McKesson Corporation $MCK

KLP Kapitalforvaltning AS lessened its holdings in McKesson Corporation (NYSE:MCK) by 0.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 78,470 shares of the company’s stock after selling 740 shares during the period. KLP Kapitalforvaltning AS’s holdings in McKesson were worth $64,423,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in MCK. Brighton Jones LLC raised its stake in McKesson by 46.3% in the 4th quarter. Brighton Jones LLC now owns 2,523 shares of the company’s stock valued at $1,438,000 after acquiring an additional 798 shares during the period. Caxton Associates LLP bought a new stake in McKesson in the 1st quarter valued at $233,000. Sivia Capital Partners LLC raised its stake in McKesson by 77.9% in the 2nd quarter. Sivia Capital Partners LLC now owns 685 shares of the company’s stock valued at $502,000 after acquiring an additional 300 shares during the period. Treasurer of the State of North Carolina raised its stake in McKesson by 0.9% in the 2nd quarter. Treasurer of the State of North Carolina now owns 58,623 shares of the company’s stock valued at $42,958,000 after acquiring an additional 508 shares during the period. Finally, Osterweis Capital Management Inc. bought a new stake in McKesson in the 2nd quarter valued at $166,000. Institutional investors own 85.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on MCK shares. Raymond James Financial set a $970.00 price objective on McKesson in a research report on Thursday, March 5th. Bank of America lowered their price objective on McKesson from $1,040.00 to $1,000.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Morgan Stanley reiterated an “overweight” rating and set a $966.00 price objective on shares of McKesson in a research report on Thursday, January 29th. Mizuho increased their price objective on McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a research report on Thursday, February 5th. Finally, Weiss Ratings cut McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research report on Thursday, February 5th. Thirteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, McKesson has a consensus rating of “Moderate Buy” and a consensus target price of $970.93.

Insider Buying and Selling

In other news, EVP Michele Lau sold 2,725 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the sale, the executive vice president directly owned 3,247 shares of the company’s stock, valued at approximately $3,214,530. This represents a 45.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Maria Martinez sold 349 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total value of $328,014.63. Following the sale, the director directly owned 301 shares in the company, valued at approximately $282,900.87. This trade represents a 53.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 3,592 shares of company stock valued at $3,518,555. Company insiders own 0.08% of the company’s stock.

McKesson Price Performance

MCK stock opened at $842.59 on Wednesday. The stock has a market capitalization of $103.21 billion, a price-to-earnings ratio of 24.23, a PEG ratio of 1.24 and a beta of 0.42. The business’s fifty day moving average price is $910.28 and its two-hundred day moving average price is $856.99. McKesson Corporation has a fifty-two week low of $637.00 and a fifty-two week high of $999.00.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.19 by $0.15. The company had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.McKesson’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the firm posted $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Research analysts expect that McKesson Corporation will post 39.02 EPS for the current year.

McKesson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd were issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend was Monday, March 2nd. McKesson’s dividend payout ratio is 9.43%.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Apollo to buy a minority stake (~13%) in McKesson’s Medical‑Surgical Solutions business for $1.25 billion — validates the MMS spinoff plan, provides liquidity ahead of the IPO, and brings an external investor endorsement that may de‑risk the separation. McKesson sells minority stake in surgical supplies unit to Apollo Funds for $1.25 billion
• Positive Sentiment: Company press release/coverage confirms the definitive agreement with Apollo and frames the transaction as a milestone toward the planned MMS IPO — signals management is executing the separation strategy and unlocking value. McKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutions
• Positive Sentiment: Analysts expect McKesson to report another strong quarter next month with projected double‑digit profit growth — a near‑term catalyst that could reverse weakness if results beat expectations. McKesson Earnings Preview: What to Expect
• Neutral Sentiment: Longer‑term analyst pieces highlight McKesson’s compounding track record (double‑digit EPS growth and management’s shareholder value creation) — supportive for investors focused on multi‑year returns but less immediately market‑moving. Is McKesson Stock Still A High-Conviction Compounder?
• Neutral Sentiment: Standalone comparisons and sector articles (e.g., head‑to‑head with CONMED) provide context but are unlikely to move the stock materially by themselves. McKesson versus CONMED Head to Head Comparison
• Negative Sentiment: Market reaction: coverage notes McKesson is trading down more than the broader market today — the stock has pulled back from near‑term highs as investors digest the MMS transaction details, timing of the spinoff, and broader market moves. McKesson (MCK) Sees a More Significant Dip Than Broader Market

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.